- RecruitingPHASE3
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
This study looks at new treatments for a severe type of childhood arthritis called Systemic Juvenile Idiopathic Arthritis (sJIA). It compares upadacitinib with an existing treatment, tocilizumab, to see how well they work and if they cause any side effects in children aged 1 to 17.
For: Juvenile Idiopathic ArthritisUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
This study is looking at a new medicine called baricitinib for children aged 1 to 17 with a type of arthritis called systemic juvenile idiopathic arthritis (sJIA). It aims to see if baricitinib is safe and helps to reduce their symptoms.
For: Systemic Juvenile Idiopathic ArthritisArgentina · Belgium · Brazil - RecruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.
For: Metastatic Breast CancerUnited States · Australia · France - Active not recruitingPHASE1
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
This study is looking at a new medicine called RO7507062 for people with Systemic Lupus Erythematosus (SLE). It aims to see how safe the medicine is, how well bodies cope with it, and what it does in the body. This is an early stage study.
For: Systemic Lupus ErythematosusColombia · France · Germany - RecruitingPHASE3
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
This study is for children aged 2-17 with a type of arthritis called JIA, who haven't fully responded to their first TNF inhibitor medicine. It compares different existing medicines to find the best next steps for treatment.
For: Polyarticular Course Juvenile Idiopathic Arthritis (JIA)United States · Germany · Italy - Active not recruitingPHASE2
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
This study looks at a new drug, Glofitamab, combined with standard treatment for a type of lymphoma called DLBCL. It aims to see if this new combination is safe and effective for patients who haven't been treated before and have a high-risk form of the disease.
For: LymphomaUnited States · Denmark · France - Active not recruitingPHASE1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
This study looks at a new drug, Cevostamab, for people with multiple myeloma that has come back or not responded to previous treatments. It aims to check its safety, how it moves in the body, and if it helps when given alone or with other medicines.
For: Multiple MyelomaUnited States · Australia · Canada - RecruitingPHASE1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
This study is testing new combinations of medicines for a type of blood cancer called Non-Hodgkin Lymphoma. It aims to see how safe and effective these new treatments are, and how the body handles them. It's for people whose cancer hasn't responded well to previous treatments.
For: Non-Hodgkin LymphomaUnited States · Israel · Italy - RecruitingPHASE1
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
This study is testing a new type of cell therapy called BMS-986515 for severe autoimmune diseases like lupus and arthritis. Doctors want to find out if it's safe, what dose works best, and if it can help people whose current treatments aren't effective.
For: Refractory Autoimmune DiseasesUnited States · Australia · Brazil - Active not recruitingPHASE1, PHASE2
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This study looks at new drug combinations for adults with a type of blood cancer called Non-Hodgkin's Lymphoma that has come back or not responded to previous treatments. It aims to find the safest dose and see how well these new treatments work.
For: Non-Hodgkins LymphomaBelgium · Denmark · Israel - Active not recruitingPHASE1, PHASE2
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
This study looks at new drug combinations to treat B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. We want to see how safe and effective these new treatments are, especially when other treatments haven't worked.
For: B-cell Non-Hodgkin LymphomaUnited States · Belgium · Canada - Active not recruitingPHASE1
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
This study is looking at a new medicine called Runimotamab for people with certain advanced HER2-positive cancers. It aims to see if it's safe and how it works, both alone and with other treatments like Trastuzumab.
For: Solid TumorsUnited States · Australia · Belgium - Active not recruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
This study looks at a new medicine called cevostamab for people with multiple myeloma that has come back or isn't responding to treatment. It checks how well it works and if it's safe when given through a drip.
For: Multiple MyelomaUnited States · Australia · Belgium - RecruitingPHASE4
Plan Development for Giving Teclistamab in the Outpatient Setting
This study is looking at how to give a cancer medicine called teclistamab to people with multiple myeloma at home or at an outpatient clinic. It also wants to understand how this affects their caregivers.
For: Multiple Myeloma · Relapsed Cancer · Refractory CancerCanada - RecruitingPHASE1
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
This study is testing a new cell therapy called CC-97540 for severe autoimmune diseases like lupus and rheumatoid arthritis. It aims to see if it's safe, how well it works, and how the body handles it, especially when other treatments haven't helped.
For: Systemic Lupus Erythematosus · Idiopathic Inflammatory Myopathy · Systemic SclerosisUnited States · Belgium · France - Recruiting
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
This study looks at how medicines mothers take get into breast milk and affect their babies. We need breastfeeding mums taking common drugs to help us learn more about drug levels in milk and babies, to ensure safer choices for mums and their infants.
For: Lactating Women on Select DOI · Breastfed Infants of Mothers on Select DOIUnited States · Canada - RecruitingPHASE1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
This study looks at a new treatment called mosunetuzumab for chronic lymphocytic leukemia (CLL) that has come back or not responded to previous treatments. It checks how safe it is, how well it works, and how the body handles it, sometimes used with another drug, venetoclax.
For: Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaUnited States · Australia · China - Active not recruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This study looks at new drug combinations for people with certain types of Non-Hodgkin's Lymphoma that have come back or not responded to previous treatments. It aims to check safety and how well the new treatments work.
For: Lymphoma, Non-HodgkinUnited States · Australia · Belgium - AuthorisedTherapeutic use (Phase IV)
Concentration guided dose reduction versus standard dosing in tocilizumab treated heumatoid arthritis patients:a randomised, international, multicenter, non-inferiority trial
This study compares two ways of giving tocilizumab for rheumatoid arthritis: adjusting the dose based on blood levels vs. standard dosing. We want to see if adjusting the dose works just as well and is safe, helping to find the best treatment plan for patients.
For: Rheumatoid arthritisNetherlands - Active not recruitingPHASE1, PHASE2
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
This study looks at new drug combinations for follicular lymphoma. It checks how safe they are, how well they work, and how the body handles them. Researchers are comparing different ways to give one of the drugs.
For: Follicular LymphomaUnited States · China · France - Active not recruitingPHASE3
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study looks at a new drug, glofitamab, combined with standard chemotherapy (GemOx) for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatments. It compares this new combination to a standard treatment.
For: Diffuse Large B-cell LymphomaUnited States · Australia · Belgium - RecruitingPHASE3
Randomised Evaluation of COVID-19 Therapy
The RECOVERY trial looks at treatments for serious lung infections like pneumonia, including COVID-19. It helps doctors find the best ways to help hospitalised patients get better and reduce their risk of dying. Many treatments have been tested, and some have been found to be very helpful.
For: PneumoniaBelgium · Estonia · France - RecruitingPHASE1, PHASE2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
This study is testing a new drug, ubamatamab, alone or with cemiplimab, for recurrent ovarian or endometrial cancer. It aims to see how safe it is, how it works in the body, and if it can help treat these cancers.
For: Recurrent Ovarian Cancer · Recurrent Fallopian Tube Cancer · Recurrent Primary Peritoneal CancerUnited States · Australia · Belgium - RecruitingPHASE3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
This study, called REMAP-CAP, looks at different treatments for serious lung infections like pneumonia, flu, and COVID-19 in adults needing intensive care. It aims to find out which treatments work best to help patients recover.
For: Community-acquired Pneumonia, Influenza, COVID-19United States · Australia · Belgium - Not yet recruitingPHASE3
COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"
This study looks at two existing drugs, anakinra and tocilizumab, to treat a rare, severe seizure condition called NORSE. It aims to find out which drug works better and when it should be given, as NORSE doesn't respond to usual treatments.
For: New Onset Refractory Status Epilepticus · New-Onset Refractory Status Epilepticus · Febrile Infection-Related Epilepsy Syndrome (FIRES)United States · Canada · France - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
This study looks at a new treatment called BMS-986353 for severe Systemic Sclerosis. It compares this new treatment with standard care to see if it's more effective and safe for people with this condition.
For: Systemic SclerosisUnited States · Belgium · Canada - RecruitingPHASE3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
This study is testing a new medicine, glofitamab, for people in the UK with a type of blood cancer called mantle cell lymphoma. It aims to see if glofitamab works better than standard treatments for those whose cancer has returned or isn't responding to past therapies.
For: LymphomaUnited States · Australia · Brazil - RecruitingPhase II
A trial to test tocilizumab, an anti-inflammatory medication, in understanding how controlling the whole body's inflammation can prevent inflammation damage to the brain following head injury
This study is looking at whether an anti-inflammatory medicine called tocilizumab could help people with a severe head injury. It's hoped that by reducing inflammation in the brain, it might help with recovery. This is an early study to see if the medicine works in this way, with plans for a bigger trial later.
For: Traumatic brain injuryUnited Kingdom · England